Phase not reported / not applicableActive, not recruitingOBSERVATIONAL
Comparative Effectiveness and Safety of Four Second Line Pharmacological Strategies in Type 2 Diabetes Study
ClinicalTrials.gov · NCT05220917 · Registry updated: 2026-08-13
- Condition / research focus
- Cardiovascular Events; Type2 Diabetes; Renal Disease
- Sponsor
- Brigham and Women's Hospital
- Countries with listed sites
- United States
- Registry dates and results
- Start: 2021-08-01. Completion: 2027-09-30 (may be estimated). No results posted in this registry response.
Products and interventions (4)
Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.
- SGLT2 inhibitor (drug) — also listed as: CANAGLIFLOZIN, CANAGLIFLOZIN/METFORMIN HCL, DAPAGLIFLOZIN PROPANEDIOL/METFORMIN HCL, DAPAGLIFLOZIN PROPANEDIOL, EMPAGLIFLOZIN, EMPAGLIFLOZIN/METFORMIN HCL, ERTUGLIFLOZIN PIDOLATE/METFORMIN HCL, ERTUGLIFLOZIN PIDOLATE, EMPAGLIFLOZIN/LINAGLIPTIN, EMPAGLIFLOZIN/LINAGLIPTIN/METFORMIN HCL, DAPAGLIFLOZIN PROPANEDIOL/SAXAGLIPTIN HCL, ERTUGLIFLOZIN PIDOLATE/SITAGLIPTIN PHOSPHATE
- DPP-4 inhibitor (drug) — also listed as: ALOGLIPTIN BENZOATE/METFORMIN HCL, ALOGLIPTIN BENZOATE, ALOGLIPTIN BENZOATE/PIOGLITAZONE HCL, SAXAGLIPTIN HCL, SAXAGLIPTIN HCL/METFORMIN HCL, LINAGLIPTIN, LINAGLIPTIN/METFORMIN HCL, SITAGLIPTIN PHOSPHATE/METFORMIN HCL, SITAGLIPTIN PHOSPHATE, SITAGLIPTIN PHOSPHATE/SIMVASTATIN, DAPAGLIFLOZIN PROPANEDIOL/SAXAGLIPTIN HCL, EMPAGLIFLOZIN/LINAGLIPTIN, EMPAGLIFLOZIN/LINAGLIPTIN/METFORMIN HCL, ERTUGLIFLOZIN PIDOLATE/SITAGLIPTIN PHOSPHATE
- GLP-1RA (drug) — also listed as: INSULIN DEGLUDEC/LIRAGLUTIDE*, INSULIN GLARGINE, HUMAN RECOMBINANT ANALOG/LIXISENATIDE*, LIXISENATIDE, LIRAGLUTIDE, DULAGLUTIDE, SEMAGLUTIDE, ALBIGLUTIDE, EXENATIDE MICROSPHERES, EXENATIDE
- 2nd generation SU (drug) — also listed as: PIOGLITAZONE HCL/GLIMEPIRIDE, ROSIGLITAZONE MALEATE/GLIMEPIRIDE, GLIPIZIDE/METFORMIN HCL, GLYBURIDE,MICRONIZED, GLYBURIDE/METFORMIN HCL, GLIMEPIRIDE, GLYBURIDE, GLIPIZIDE
Where the study takes place — 1 listed sites
Site status can differ from overall study status. This list includes all reported sites, even when your search specifies one location. Confirm availability and eligibility with the study team through the original record.
- Brigham and Women's Hospital
Boston, Massachusetts, United States
Site recruitment: Not reported